BRAF and neoplasm: Similarly, an immunomodulatory effect of dasatinib on T cells has been associated with improved anti-tumor immunity (67, 68), and BRAF/MEK inhibition in patients with melanoma leads to upregulation of TCF7 and expansion of melanoma-specific TIL (69).